Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10380 Phase I in healthy Chinese adults
NCT05480592Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Aug 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of obuprazine in schizophrenia (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Number of Subjects Experiencing Adverse Events (AEs), Changes from baseline in laboratory tests and 6 more. Status: unknown.
02
Drugs
obuprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05480592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05480592.